$ACIU
AC Immune SA
XNAS•Health Care•Pharmaceutical Preparations
$2.63
▼-1.87%-$0.050
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateWhy is ACIU down today? It is at $2.63 (-1.87%), and our scanner flagged it 2 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ACIU spikes, and full due diligence on ACIU — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ACIU 2 times in the last 30 days. Create a free account to track $ACIU, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on ACIU from our scanner (live price and day move above). A recent catalyst in the news: “XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback.”
Latest filing6-KForeign issuer report (6-K)Sep 3, 2026 · 15 days ago| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
June Carl Howard Director | Acquired (grant/award) | +17K 0.02% of company | added 32% | 68K | n/a | Jun 11, 26 |
Buetler Monika Director | Acquired (grant/award) | +18K 0.02% of company | added 33% | 72K | n/a | Jun 11, 26 |
Zuegel Martin Officer | Acquired (grant/award) | +33K 0.03% of company | added 87% | 71K | n/a | Jun 11, 26 |
Aguiar-Lucander Renee Director | Acquired (grant/award) | +17K 0.02% of company | added 48% | 51K | n/a | Jun 11, 26 |
Twyman Roy Ervin Director | Acquired (grant/award) | +17K 0.02% of company | added 22% | 93K | n/a | Jun 11, 26 |
Pfeifer Andrea Officer | Sold (automatic/other) | -10K 0.01% of company | sold 0.3% | 3.82M | $28K at $2.79 | May 15, 26 |
Pfeifer Andrea Officer | Bought (open market) | +10K 0.01% of company | added 0.3% | 3.83M | $31K at $3.14 | Apr 15, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on ACIU from our scanner (live price and day move above). A recent catalyst in the news: “XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback.”
ACIU last traded at $2.63, down 1.87% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
AC Immune SA (ACIU) is next expected to report earnings on Tuesday, November 3, 2026, about 45 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ACIU Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ACIU 2 times in the last 30 days.
ACIU (AC Immune SA) trades on XNAS, with a market cap of about $266M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ACIU for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ACIU discussion
Sign in to ask a question or join the discussion.